PD-1 and its ligands in tolerance and immunity

Area of Science:

• Immunology
• Molecular Biology
• Cellular Biology

Background:

• Programmed death 1 (PD-1) and its ligands (PD-L1, PD-L2) are critical regulators of T cell responses, maintaining immune homeostasis.
• The PD-1:PD-L pathway balances T cell activation, tolerance, and prevents immunopathology, crucial for distinguishing self from foreign antigens.
• Dysregulation of this pathway by tumors or pathogens can lead to immune evasion and chronic conditions.

Purpose of the Study:

• To review the immunoregulatory functions of the PD-1:PD-L pathway.
• To discuss the newly identified interactions between PD-L1 and B7-1.
• To explore the therapeutic potential of targeting the PD-1:PD-L axis.

Main Methods:

• Literature review of existing research on PD-1 and its ligands.
• Analysis of studies detailing the PD-1:PD-L1 and PD-L1:B7-1 interactions.
• Synthesis of findings on the role of these pathways in immune regulation and disease.

Main Results:

• PD-1 is essential for inducing and maintaining T cell tolerance.
• PD-L1 on non-hematopoietic cells limits effector T cell responses, protecting tissues from damage.
• The PD-1:PD-L pathway is exploited by pathogens and tumors to suppress immunity.
• A novel bidirectional inhibitory interaction between PD-L1 and B7-1 has been identified, expanding understanding of B7:CD28 family regulation.

Conclusions:

• The PD-1:PD-L pathway plays a multifaceted role in immune regulation, encompassing tolerance, tissue protection, and immune evasion.
• The discovery of PD-L1:B7-1 interactions provides new insights into T cell activation and tolerance mechanisms.
• Targeting the PD-1:PD-L axis holds significant therapeutic promise for various immunological disorders and cancer.